This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:596.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved sertraline hydrochloride (Zoloft, Pfizer Inc, New York, NY) as the first drug treatment for posttraumatic stress disorder (PTSD). The drug had been approved to treat depression, obsessive compulsive disorder, and panic disorder.

According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, a diagnosis of PTSD requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response of intense fear, helplessness, or horror. Symptoms of PTSD, which must be present for more than 1 month, include reexperiencing and intrusion of the traumatic event; avoidance of situations reminiscent of it; numbing of general responsiveness; irritability; sleep disturbance; impaired concentration; and outbursts of anger. The disturbance must cause clinically significant distress or impairment of functioning.

The effectiveness of sertraline in the treatment of PTSD was . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?